Zymeworks' ZW191 Shows Strong Early Efficacy in Ovarian and Endometrial Cancers — Zymeworks Inc.

Event summary

Zymeworks presented Phase 1 data for ZW191 at the AACR Annual Meeting 2026, showing a confirmed objective response rate (cORR) of 61% in platinum-resistant ovarian cancer patients.
Median progression-free survival was 7.6 months across ovarian and endometrial cancer cohorts, with responses observed regardless of folate receptor alpha (FRα) expression levels.
ZW191 demonstrated a favorable tolerability profile, with severe adverse events occurring in 55% of patients, primarily grade 3 neutropenia, anemia, and thrombocytopenia.

The big picture

Zymeworks' Phase 1 data for ZW191 highlights the potential of FRα-targeting ADCs in heavily pretreated gynecological cancers. The results position ZW191 as a competitive candidate in a space dominated by established therapies, with the added advantage of efficacy across varying levels of FRα expression. This development aligns with broader industry trends toward precision oncology and differentiated payload designs in antibody-drug conjugates.

What we're watching

Clinical Development Pathway: Whether Zymeworks can secure regulatory approval for ZW191 based on the Phase 1 data, particularly given the broad patient population response.
Market Differentiation: How Zymeworks positions ZW191 against existing FRα-targeting therapies in ovarian and endometrial cancers.
Partnership Strategy: The pace at which Zymeworks advances partnerships for ZW191, leveraging its existing collaborations with BeOne Medicines and Jazz Pharmaceuticals.